瑞舒伐他汀联合缬沙坦治疗冠心病的效果及对糖脂代谢的影响

Effect of Rosuvastatin Combined with Valsartan in the Treatment of Coronary Heart Disease and the Impact on Glucose and Lipid Metabolism

目的探讨瑞舒伐他汀联合缬沙坦治疗冠心病(CHD)的效果及对糖脂代谢的影响。方法选取2020年10月至2023年10月本院收治的98例CHD患者,按照奇偶顺序分为两组。对照组采用缬沙坦治疗,观察组采用缬沙坦联合瑞舒伐他汀。比较两组的斑块面积、糖脂代谢指标及心功能指标。结果治疗后,观察组脂质、钙化、混合斑块面积低于对照组(P<0.05)。治疗后,观察组TG、LDL-C、FPG、HbA1c水平低于对照组(P<0.05)。治疗后,观察组BNP低于对照组,LVEF高于对照组(P<0.05)。结论瑞舒伐他汀联合缬沙坦治疗CHD效果确切,可缩小冠脉斑块面积,调节糖脂代谢,改善患者心功能。

Objective To explore the effect of rosuvastatin combined with valsartan in the treatment of coronary heart disease(CHD)and the impact on glucose and lipid metabolism.Methods 98 CHD patients admitted to our hospital from October 2020 to October 2023 were divided into two groups according to parity order.The control group was treated with valsartan,and the observation group was treated with valsartan combined with rosuvastatin.The plaque area,glucose and lipid metabolism indicators,and cardiac function indicators were compared between the two groups.Results After treatment,the area of lipid,calcification and mixed plaque in the observation group were lower than those in the control group(P<0.05).After treatment,the TG,LDL-C,FPG and HbA1c levels of the observation group were lower than those of the control group(P<0.o5).After treatment,the BNP of the observation group was lower than that of control group,and the LVEF was higher than that of the control group(P<0.05).Conclusions Rosuvastatin combined with valsartan has exact effect in the treatment of CHD,which can reduce the coronary plaque area,regulate the glucose and lipid metabolism,and improve the cardiac function.